Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    80405
Show Display Options
Rank Status Study
1 Active, not recruiting Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab;   Biological: cetuximab;   Drug: FOLFOX or;   Drug: FOLFIRI
2 Unknown  Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Genetic: mutation analysis;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years